| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0168-0102(01)00254-1 |
| P698 | PubMed publication ID | 11535288 |
| P2093 | author name string | Shastry BS | |
| P2860 | cites work | RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination | Q22010577 |
| Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase | Q22254584 | ||
| Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1 | Q24290518 | ||
| Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 | ||
| Functional recovery in parkinsonian monkeys treated with GDNF | Q24312738 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| The engagement of Sec61p in the ER dislocation process | Q27932365 | ||
| Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17 | Q28274687 | ||
| Parkinson disease in twins: an etiologic study | Q28296110 | ||
| A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease | Q28371129 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
| Aggresomes, inclusion bodies and protein aggregation | Q29615253 | ||
| Association between early-onset Parkinson's disease and mutations in the parkin gene | Q29615733 | ||
| A Drosophila model of Parkinson's disease | Q29617052 | ||
| Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family | Q30472923 | ||
| A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia. | Q31859176 | ||
| Aggregates in neurodegenerative disease: crowds and power? | Q33633045 | ||
| Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations | Q33893738 | ||
| Progress in the clinical and molecular genetics of familial parkinsonism | Q34030090 | ||
| Association of coffee and caffeine intake with the risk of Parkinson disease | Q34508881 | ||
| Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity | Q37597604 | ||
| Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects | Q39412774 | ||
| ??? | Q64779071 | ||
| ??? | Q64862721 | ||
| Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease | Q39429074 | ||
| Progression of parkinsonism and loss of cognitive function in Alzheimer disease | Q39540404 | ||
| Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal | Q40758643 | ||
| Biomedicine. Combating Parkinson's disease--step three | Q40826182 | ||
| Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate | Q40842073 | ||
| Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease | Q40846012 | ||
| Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. | Q40866683 | ||
| Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain | Q41379201 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Tau is a candidate gene for chromosome 17 frontotemporal dementia | Q42456776 | ||
| Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene | Q42626667 | ||
| Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase | Q43185222 | ||
| Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein | Q43218554 | ||
| The cellular chamber of doom. | Q43513552 | ||
| A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa | Q45087241 | ||
| A one-hit model of cell death in inherited neuronal degenerations | Q45300872 | ||
| Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity | Q46070812 | ||
| The ubiquitin pathway in Parkinson's disease | Q48015939 | ||
| Point mutations of mitochondrial genome in Parkinson's disease | Q48075275 | ||
| Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene | Q48398668 | ||
| Dopaminergic neurons intrinsic to the primate striatum. | Q48633399 | ||
| Mitochondrial DNA polymorphism in substantia nigra | Q48844431 | ||
| Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons | Q48937244 | ||
| Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease | Q49085090 | ||
| Opportunism knocks? | Q59079003 | ||
| Molecular genetic analysis of a novelParkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in theParkin gene in affected individuals | Q60684231 | ||
| Dopamine agonists in early therapy for Parkinson disease: promise and problems | Q64767712 | ||
| Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients | Q64778242 | ||
| Treatment of early Parkinson's disease | Q64779682 | ||
| GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset | Q64787846 | ||
| Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease | Q64866906 | ||
| Mitochondrial oxidative phosphorylation defects in Parkinson's disease | Q68060626 | ||
| Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease | Q69356679 | ||
| Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions | Q73189206 | ||
| Prevalence of homozygous deletions of the parkin gene in a cohort of patients with sporadic and familial Parkinson's disease | Q73532938 | ||
| Exonic deletion mutations of the Parkin gene among sporadic patients with Parkinson's disease | Q73807460 | ||
| P433 | issue | 1 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| gene therapy | Q213901 | ||
| P304 | page(s) | 5-12 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Neuroscience Research | Q15764280 |
| P1476 | title | Parkinson disease: etiology, pathogenesis and future of gene therapy | |
| P478 | volume | 41 |
| Q38834490 | A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro |
| Q33517934 | Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease |
| Q40694627 | Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease |
| Q80223133 | Alpha-synuclein overexpression increases cytosolic catecholamine concentration |
| Q33754643 | Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity |
| Q35579333 | Can zebrafish be used as a model to study the neurodevelopmental causes of autism? |
| Q48794611 | Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model |
| Q48265381 | Clinical improvement of the aggressive neurobehavioral phenotype in a patient with a deletion of PITX3 and the absence of L-DOPA in the cerebrospinal fluid. |
| Q39121710 | Commonalities in biological pathways, genetics, and cellular mechanism between Alzheimer Disease and other neurodegenerative diseases: An in silico-updated overview |
| Q61814548 | Cyclodextrins in Parkinson's Disease |
| Q47754459 | Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease |
| Q37401787 | Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins |
| Q40245982 | Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy |
| Q73260280 | Etiology of Parkinson's Disease |
| Q40627675 | Fe(II)‐induced DNA damage in α‐synuclein‐transfected human dopaminergic BE(2)‐M17 neuroblastoma cells: detection by the Comet assay |
| Q37731033 | Feasibility study of a wearable system based on a wireless body area network for gait assessment in Parkinson's disease patients |
| Q40204577 | GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease |
| Q30481214 | Gait dynamics in Parkinson's disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling |
| Q33857756 | Glial cell line-derived neurotrophic factor gene delivery via a polyethylene imine grafted chitosan carrier |
| Q52653180 | High resolution electrospray and electrospray tandem mass spectra of rotenone and its isoxazoline cycloadducts. |
| Q42565249 | ICP10PK inhibits calpain-dependent release of apoptosis-inducing factor and programmed cell death in response to the toxin MPP+. |
| Q34211646 | Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. |
| Q35791901 | Is there a connection between estrogen and Parkinson's disease? |
| Q48483209 | MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions. |
| Q42726539 | MPTP-induced models of Parkinson's disease in mice and non-human primates |
| Q35550669 | Metabolic Engineering: Advances in Modeling and Intervention in Health and Disease |
| Q41922855 | Naringin Protects against Rotenone-induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells |
| Q28212108 | Neurodegenerative disorders of protein aggregation |
| Q40540903 | Overexpression of synuclein-gamma in pancreatic adenocarcinoma |
| Q39806409 | Parkinson's disease: is it a toxic syndrome? |
| Q42408260 | Possible involvement of a mitochondrial translation initiation factor 3 variant causing decreased mRNA levels in Parkinson's disease |
| Q45859214 | Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease |
| Q85174010 | Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy |
| Q39938152 | Protective effects of asiatic acid on rotenone- or H2O2-induced injury in SH-SY5Y cells |
| Q37110410 | Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease |
| Q57547539 | Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC–MS/MS method |
| Q33613315 | The rat striatum responds to nigro-striatal degeneration via the increased expression of proteins associated with growth and regeneration of neuronal circuitry |
| Q36045429 | Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy |
| Q35111639 | Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs |
| Q36639486 | Verbascoside promotes the regeneration of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra |
| Q34398041 | Wearability assessment of a wearable system for Parkinson's disease remote monitoring based on a body area network of sensors |
| Q28264682 | alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease |
Search more.